Ofrat Katz-Beyar

Haifa, HA, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 65 publications

Safety and outcomes of CD19 CAR-T cell therapy in splenectomized patients with B-cell lymphomas.

Safety and outcomes of CD19 CAR-T cell therapy in splenectomized patients with B-cell lymphomas.

Journal: Transplantation and cellular therapy

Published: April 24, 2026

Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.

Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.

Journal: Transplantation and cellular therapy

Published: March 13, 2026

Impact of ASTCT Toxicity Grading System on Outcomes After CAR-T for Mature B-Cell Malignancies.

Impact of ASTCT Toxicity Grading System on Outcomes After CAR-T for Mature B-Cell Malignancies.

Journal: Transplantation and cellular therapy

Published: March 04, 2026

Impact of ASTCT toxicity grading system on outcomes after CAR-T for mature B-cell malignancies.

Impact of ASTCT toxicity grading system on outcomes after CAR-T for mature B-cell malignancies.

Journal: Transplantation and cellular therapy

Published: March 04, 2026

Multiplex edited universal CAR T cells without the genomic cost.

Multiplex edited universal CAR T cells without the genomic cost.

Journal: Haematologica

Published: February 13, 2026

Outcomes of Salvage Therapy after Early-Line CD19 Chimeric Antigen Receptor T-Cell Failure in Large B-Cell Lymphoma.

Outcomes of Salvage Therapy after Early-Line CD19 Chimeric Antigen Receptor T-Cell Failure in Large B-Cell Lymphoma.

Journal: Transplantation and cellular therapy

Published: February 02, 2026

Outcomes of Salvage Therapy after Early-Line CD19 Chimeric Antigen Receptor T-Cell Failure in Large B-Cell Lymphoma.

Outcomes of Salvage Therapy after Early-Line CD19 Chimeric Antigen Receptor T-Cell Failure in Large B-Cell Lymphoma.

Journal: Transplantation and cellular therapy

Published: February 02, 2026

Platelet and Fibrinogen Dynamics After CAR-T Cell Therapy in Relapsed/Refractory B-Cell Lymphoma May Predict ICANS Onset.

Platelet and Fibrinogen Dynamics After CAR-T Cell Therapy in Relapsed/Refractory B-Cell Lymphoma May Predict ICANS Onset.

Journal: European journal of haematology

Published: November 19, 2025

CD19 CAR T-Cell Therapy in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.

CD19 CAR T-Cell Therapy in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.

Journal: American journal of hematology

Published: November 05, 2025

Respiratory Syncytial Virus After CAR T-cell therapy: Risk Factors and Outcomes in a Multicenter Retrospective Cohort.

Respiratory Syncytial Virus After CAR T-cell therapy: Risk Factors and Outcomes in a Multicenter Retrospective Cohort.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: November 03, 2025

Respiratory Syncytial Virus After Chimeric Antigen Receptor T-cell Therapy: Risk Factors and Outcomes in a Multicenter Retrospective Cohort.

Respiratory Syncytial Virus After Chimeric Antigen Receptor T-cell Therapy: Risk Factors and Outcomes in a Multicenter Retrospective Cohort.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: November 03, 2025

Distinct cellular signatures in aplastic and intermittent phenotypes of immune effector cell-associated hematotoxicity.

Distinct cellular signatures in aplastic and intermittent phenotypes of immune effector cell-associated hematotoxicity.

Journal: Annals of hematology

Published: October 15, 2025

Showing 1-12 of 65

Last Updated: 09/26/2026